Securities code: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022031
Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
Suggestive announcement on the unilateral termination of the issuance of shares and the payment of cash to purchase assets by the counterparty
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”) intends to issue shares and pay cash to purchase 60% equity of Jiangsu weidekang Medical Technology Co., Ltd. (hereinafter referred to as “the target company”) jointly held by Changzhou beiruishi Enterprise Management Co., Ltd., Changzhou Yiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin (hereinafter referred to as “the counterparty”).
On November 19, 2021, the company held the 17th meeting of the 5th board of directors and the 16th meeting of the 5th board of supervisors, deliberated and adopted the proposal on continuing to promote the issue of shares and payment of cash to purchase assets, and agreed to continue to promote this transaction. Please refer to the announcement of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) on continuing to promote the issue of shares and paying cash to purchase assets (Announcement No.: 2021088) issued by the company on November 20, 2021.
On December 18, 2021, January 18, 2022, February 18, 2022 and March 18, 2022, the company has issued the progress announcement of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) on issuing shares and paying cash to purchase assets (Announcement No.: 2021095, 2022002, 2022019 and 2022027).
Recently, the company received a notice from the counterparty that it unilaterally requested to terminate the relevant agreement of this transaction. The company is communicating with the counterparty, but no substantive progress has been made. If both parties fail to reach an agreement through negotiation, the company will file a lawsuit against its unilateral termination of this transaction as soon as possible and investigate its relevant legal liabilities.
The above changes of the counterparty will lead to significant uncertainty whether the transaction can continue to advance, and there is a risk of termination of the transaction.
The information disclosure media designated by the company are securities times, securities daily and http://www.cn.info.com.cn, All information of the company shall be subject to the announcement published in the above designated media. Please pay attention to the follow-up announcement and pay attention to the investment risk.
It is hereby announced.
Beijing Aosaikang Pharmaceutical Co.Ltd(002755) board of directors April 17, 2022
